Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.46 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289373 | 0.86 | L3MBTL1 (0.55) | MAOBL3MBTL1ROCK2NAMPTPTGER4 | |
| SCHEMBL6288790 | 0.74 | MAOB (0.48) | MAOBL3MBTL1ROCK2CACNA1GCACNA1H | |
| SCHEMBL6288983 | 0.72 | PTGER4 (0.40) | MAOBL3MBTL1S1PR3CACNA1GCACNA1H | |
| SCHEMBL6289015 | 0.71 | MMP13 (0.50) | MAOBROCK2 | |
| SCHEMBL14345990 | 0.71 | L3MBTL1 (0.80) | MAOBL3MBTL1ROCK2NAMPT | |
| SCHEMBL5330099 | 0.70 | L3MBTL1 (1.00) | MAOBL3MBTL1ROCK2NAMPT | |
| SCHEMBL6289376 | 0.70 | SMN1; SMN2 (0.45) | L3MBTL1NAMPTRXFP1 | |
| SCHEMBL6288797 | 0.69 | MEN1 (0.46) | MAOBL3MBTL1S1PR1S1PR3CACNA1G | |
| SCHEMBL6292130 | 0.68 | HDAC1 (0.51) | NAMPT | |
| SCHEMBL6699473 | 0.67 | MAOB (0.45) | MAOBL3MBTL1S1PR3CACNA1GCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949651-B2 | Fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-09-27 | — | — | US | claimed |
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | LINCOLN FOODSERVICE PRODUCTS INC. | 2004-02-19 | — | — | US | claimed |
| WO-2004014375-A2 | FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-6949651-B2 | Fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | LINCOLN FOODSERVICE PRODUCTS INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2004014375-A2 | FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | MAOB 382/4885L3MBTL1 2418/4885S1PR1 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.